GlassScriptPhysician profile
Betsy B Dodson
NPI 1912988999
$104,139.84
in general payments reported to CMS, 2019-2025
34 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,030 · 2022: $2,425 · 2023: $2,827 · 2024: $64K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Travel and Lodging: $21K · Food and Beverage: $11K · Honoraria: $2,358 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,010.00 |
| Travel and Lodging | $21,076.42 |
| Food and Beverage | $11,076.24 |
| Honoraria | $2,357.50 |
| Education | $164.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $94,097.73 | 2023-2025 | Voquezna |
| Abbvie INC. | $2,221.53 | 2021-2025 | |
| Janssen Biotech, INC. | $1,033.59 | 2021-2025 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $864.42 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $813.64 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $807.91 | 2022-2025 | Stelara, Remicade, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $642.97 | 2021-2025 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $424.34 | 2021-2025 | Suflave, Sutab |
| Lilly USA, LLC | $310.93 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $284.60 | 2021-2024 | Zeposia |
| Pfizer INC. | $260.26 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $231.21 | 2021-2024 | Ocaliva |
| Evoke Pharma, INC. | $210.98 | 2021-2025 | Gimoti |
| Genzyme Corporation | $208.52 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $206.21 | 2022-2024 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $176.18 | 2021-2024 | Dificid |
| Qol Medical, LLC | $150.93 | 2022-2023 | Sucraid |
| Celgene Corporation | $150.38 | 2021-2024 | Zeposia |
| Amgen INC. | $140.79 | 2021-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $113.00 | 2024-2025 | Iqirvo |
| Organon LLC | $111.81 | 2021-2024 | Hadlima, Renflexis |
| Medtronic, INC. | $109.19 | 2024 | Pillcam |
| Daiichi Sankyo INC. | $94.39 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $93.82 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $85.74 | 2024-2025 | Zenpep, Vowst |
| Ferring Pharmaceuticals INC. | $82.03 | 2022-2025 | Rebyota, Clenpiq |
| Laborie Medical Technologies Corp. | $49.10 | 2025 | Solar Compact |
| Celltrion USA INC. | $43.48 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $33.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.37 | 2023 | Cyltezo |
| Azurity Pharmaceuticals, INC. | $16.41 | 2025 | Suflave |
| Madrigal Pharmaceuticals | $16.38 | 2025 | Rezdiffra |
| Enterra Medical, INC. | $15.76 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.